Who are IV treatment with IGSC, 10%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PRIVIGEN (CSL Behring), IGIV GAMMAGARD LIQUID/KIOVIG, IGIV3I Grifols, LIV-GAMMA SN Inj.10%, IgNextGen 16%, Gamunex Intravenous Immunoglobulin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iv-treatment-with-igsc-10.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

IV treatment with IGSC, 10% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IV treatment with IGSC, 10% (IV treatment with IGSC, 10%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunoglobulin replacement therapy. Area: Immunology.

phase 3 Immunoglobulin replacement therapy Fc receptors, complement system, pathogenic antigens Immunology Biologic Live · refreshed every 30 min

Target snapshot

IV treatment with IGSC, 10% (IV treatment with IGSC, 10%) — Baxalta now part of Shire. IGSC 10% is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by supplying pooled human antibodies to help regulate immune function and fight infections.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IV treatment with IGSC, 10% TARGET	IV treatment with IGSC, 10%	Baxalta now part of Shire	phase 3	Immunoglobulin replacement therapy	Fc receptors, complement system, pathogenic antigens
PRIVIGEN (CSL Behring)	PRIVIGEN (CSL Behring)	Hospices Civils de Lyon	marketed	Intravenous immunoglobulin (IVIg)	Fc receptors, complement system, pathogenic antigens and antibodies
IGIV GAMMAGARD LIQUID/KIOVIG	IGIV GAMMAGARD LIQUID/KIOVIG	Baxalta now part of Shire	phase 3	Intravenous immunoglobulin (IGIV)	Fc receptors, complement system, pathogenic antigens
IGIV3I Grifols	IGIV3I Grifols	Instituto Grifols, S.A.	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens
LIV-GAMMA SN Inj.10%	LIV-GAMMA SN Inj.10%	SK Plasma Co., Ltd.	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens
IgNextGen 16%	IgNextGen 16%	CSL Limited	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens
Gamunex Intravenous Immunoglobulin	Gamunex Intravenous Immunoglobulin	National Institute of Mental Health (NIMH)	phase 3	Intravenous Immunoglobulin (IVIG)	Fc receptors, complement system, pathogenic antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunoglobulin replacement therapy class)

CSL Behring · 3 drugs in this class
Grifols Therapeutics LLC · 2 drugs in this class
Baxalta now part of Shire · 1 drug in this class
Biopharma Plasma LLC · 1 drug in this class
Sir Takhtasinhji General Hospital · 1 drug in this class
University of Edinburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IV treatment with IGSC, 10% — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-treatment-with-igsc-10. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab